Sullivan RJ, Hoshida Y, Brunet J, et al.: A single center experience with high-dose (HD) IL-2 treatment for patients with advanced melanoma and pilot investigation of a novel gene expression signature as a predictor of response. The gene discussed is IL2; the disease is melanoma.